Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the U.S. and internationally. The 52-week range of Gilead Sciences stock price was $62.07 to $119.96. Gilead Sciences' dividend yield is 3.05%. It paid $3.16 per share in dividends during the last 12 months. Don't Miss: Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Last Chance to get 4,000 of its pre-IPO shares for just $0.30/share! Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today. The Latest On Gilead Sciences On April 24, the company announced its Q1 2025 earnings, posting EPS of $1.81, beating the consensus estimate of $1.76, as reported by Benzinga. Quarterly revenue came in at $6.67 billion, which missed the analyst consensus estimate of $6.77 billion. Gilead Sciences lowered its full-year 2025 EPS guidance from a range of $5.95 to $6.35 to a range of $5.65 to $6.05, compared to the consensus of $6.21. How Can You Earn $100 Per Month As A Gilead Sciences Investor? If you want to make $100 per month — $1,200 annually — from Gilead Sciences dividends, your investment value needs to be approximately $39,344, which is around 379 shares at $103.68 each. Trending: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (3.05% in this case). So, $1,200 / 0.0305 = $39,344 to generate an income of $100 per month. You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock. The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis. For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40). In summary, income-focused investors may find Gilead Sciences stock an attractive option for making a steady income of $100 per month by owning 379 shares of stock. There may be more upside to come as investors benefit from the company's consistent dividend hikes. Gilead Sciences has raised its dividend consecutively for the last 10 years. Story Continues Check out this article by Benzinga for three more stocks offering high dividend yields. Read Next: Donald Trump Just Announced a $500 Billion AI Infrastructure Deal — Here's How You Can Invest in the Entertainment Market's Next Big Disruptor for Just $998 ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share with a $1000 minimum. Image: Shutterstock Send To MSN: 0 This article How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock originally appeared on Benzinga.com View Comments
How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...